TESTING -ON Post-Trial ObservatioNal Cohort Study
TESTING-ON
Therapeutic Evaluation of STeroids in IgA Nephropathy Global - Post-Trial ObservatioNal Cohort Study
1 other identifier
observational
211
6 countries
59
Brief Summary
The primary aim of this study is to extend follow up of TESTING study participants and to assess the long-term effects of a 6-9-month course of oral methylprednisolone on End Stage Kidney Disease (ESKD), according to dose (full-dose vs reduced-dose), ethnicity (Chinese vs other) and kidney function (eGFR above and below 60 mL/min/1.73m2).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2022
Typical duration for all trials
59 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 14, 2022
CompletedFirst Posted
Study publicly available on registry
June 28, 2022
CompletedStudy Start
First participant enrolled
December 7, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 17, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
August 30, 2025
CompletedJuly 9, 2026
June 1, 2025
2.6 years
June 14, 2022
July 7, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Primary AIM
The development of end stage kidney disease (ESKD) defined as a need for maintenance dialysis or kidney transplantation, and death due to kidney disease
Through study completion, an average of 1 year
Secondary Outcomes (6)
Secondary Aims
Through study completion, an average of 1 year
Secondary Aims
Through Study completion, an average of 1 year
Secondary Aims
Through Study Completion, an average of 1 year
Secondary Aims
Through Study Completion, an average of 1 year
Secondary Aims
Through Study Complication an average of 1 Year
- +1 more secondary outcomes
Study Arms (1)
TESTING Particpants
All participants who were successfully randomised to the TESTING study who are still alive and have not reached kidney failure requiring dialysis.
Eligibility Criteria
The population for this study will consist of all TESTING participants who do not meet any of the exclusion criteria.
You may qualify if:
- \) Only participants who were randomised into the TESTING trial
You may not qualify if:
- Participants who have reached kidney failure requiring maintenance dialysis or kidney transplantation during the TESTING trial
- Participants who died during the TESTING trial
- Participants who had withdrawn their consent during the TESTING trial
- Participants who are unable to provide consent for some other reason
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Peking University Institute of Nephrologycollaborator
- The George Institutelead
Study Sites (59)
Concord Repatriation General Hospital
Concord W., New South Wales, 2137, Australia
Nepean Hospital
Kingswood, New South Wales, 2747, Australia
Royal North Shore Hospital
St Leonards, New South Wales, 2065, Australia
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
University of Calgary/Alberta Health Services
Calgary, Alberta, T2R 0X7, Canada
University of Alberta Hospitals
Edmonton, Alberta, T6G 2B7, Canada
St Pauls Hospital
Vancouver, British Columbia, V6Z 1Y6, Canada
St. Joseph's Healthcare
Hamiliton, Ontario, L8N 4A6, Canada
London Health Sciences Centre
London, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5, Canada
Toronto General Hospital,
Toronto, Ontario, M5G 2N2, Canada
HĂ´pital Maisonneuve-Rosemont
Montreal, Quebec, H1T 2M4, Canada
Chinese PLA General Hospital (301 Hospital)
Beijing, Beijing Municipality, China
The First Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, 510080, China
Guangdong Provincial People's Hospital, Guangzhou
Guangzhou, Guangdong, China
Peking University Shenzhen Hospital
Shenzhen, Guangdong, 518036, China
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050005, China
The Third Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050051, China
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang, Henan, 471003, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Wuhan, Hubei, 430022, China
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
Renmin Hospital, Wuhan University
Wuhan, Hubei, 430060, China
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology,
Baotou, Inner Mongolia, 014010, China
Inner Mongolia People's Hospital
Hohhot, Inner Mongolia, 010017, China
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, 210029, China
Jilin Province FAW General Hospital [Jilin University Fourth Hospital]
Changchun, Jilin, 130011, China
he First Affiliated Hospital of Dalian Medical University, Dalian
Dalian, Liaoning, 116011, China
Shengjing Hospital Of China Medical University
Shengyang, Liaoning, China
Qilu Hospital of Shandong University
Jinan, Shandong, 250012, China
The First Affiliated Hospital of Shangdong First Medical University,Shangdong Provincial Qianfoshin
Jinan, Shandong, 250014, China
Shandong Provincial Hospital
Jinan, Shandong, 250021, China
Jinan Military General Hospital
Jinan, Shandong, China
The Second Hospital of Shanxi Medical University, Taiyuan
Taiyuan, Shanxi, 030001, China
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
Sichuan Academy of Medical Science, Sichuan Provincial People's Hospital
Chengdu, Sichuan, 610072, China
The First Affiliated Hospital, Zhejiang University of Medicine
Hangzhou, Zhejiang, 310003, China
Hangzhou Hospital of Traditional Chinese Medicine,
Hangzhou, Zhejiang, China
Ningbo Urology & Nephrology Hospital
Ningbo, Zhejiang, China
Zhejiang Provincial People's Hospital
Sangzhou, Zhejiang, China
Beijing Anzhen Hospital, Capital Medical University
Beijing, 100029, China
Peking University First Hospital
Beijing, 100034, China
Peking University People's Hospital
Beijing, 100035, China
Peking University Third Hospital
Beijing, China
XinQiao Hospital, Third Military Medical University
Chongqing, 400037, China
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, 200001, China
Ruijin Hospital, Shanghai Jiaotong University, School of Medicine
Shanghai, 200025, China
Princess Margaret Hospital
Kowloon, Kowloon, Hong Kong
Osmania General Hospital
Hyderabad, Andhra Pradesh, 500012, India
Nizams Institute of Medical Sciences
Hyderabad, Andhra Pradesh, 500082, India
Calicut Medical College
Kozhikode, Kerala, 673008,, India
Post Graduate Institue of Medical Education and Reasearch
Chandigarh, Punjab, 160 012, India
Madras Medical College
Chen, Tamil Nadu, 600037, India
Hospital Sultanah Aminah
Johor Bahru, Johor, 80100, Malaysia
University Malaysia Medical Centre
Kuala Lumpur, Kuala Lumpur, 59100, Malaysia
Hospital Kuala Lumpur
Kuala Lumpur, Kulala Lumpur, 50586, Malaysia
Hospital Tuanku Jaafar Seremban
Seremban, Negri Seremban, 70300, Malaysia
Hospital Raja Permaisuri Bainun
Ipoh, Perak, 30990, Malaysia
Hospital Umum Sarawak
Kuching, Samarahan, 93586, Malaysia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Hong Zhang, Prof
Peking University Institute of Nephrology
- STUDY CHAIR
Vlado Perkovic, Prof
University of New South Wales
- PRINCIPAL INVESTIGATOR
Muh Geot Wong, Dr
University of New Souht Wales
- PRINCIPAL INVESTIGATOR
Jicheng Lv
Peking University of Nephrology
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 14, 2022
First Posted
June 28, 2022
Study Start
December 7, 2022
Primary Completion
July 17, 2025
Study Completion
August 30, 2025
Last Updated
July 9, 2026
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will not share